Pirtobrutinib plus standard chemo for Richter transformation
Treatments studied
Part of Cancer clinical trials.
This trial tests adding the targeted drug pirtobrutinib to standard chemotherapy for people with newly diagnosed Richter transformation (when CLL changes into a fast-growing lymphoma). The goal is to see if this combination works better than chemo alone.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must have a diagnosis of Richter transformation (CLL turning into large B-cell lymphoma).
- You must not have received any prior treatment for Richter transformation, except a short course of steroids.
- You must have measurable disease on a PET/CT scan or lab test within the last 6 weeks.
- You must be able to swallow pills and not have serious stomach issues that affect absorption.
- You must have adequate heart, kidney, and liver function (tests will be done to check).
- You cannot have taken another BTK inhibitor (like ibrutinib) that caused major bleeding or serious heart rhythm problems.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a combination of two targeted drugs for people with Richter's transformation, an aggressive lymphoma that can develop from CLL. The goal is to see if this combination can help control the disease.
This trial studies whether polatuzumab added to chemotherapy can improve outcomes in people whose CLL/SLL has transformed into a type of aggressive lymphoma called DLBCL. It may help shrink tumors and control the disease after this transformation.
This study tests a combination of two oral drugs (nemtabrutinib and pembrolizumab) for people with Richter transformation, an aggressive lymphoma that develops from chronic lymphocytic leukemia. It may be an option if standard chemotherapy is not suitable or if prior treatment has stopped working.
This Phase 2 trial tests whether a combination of zanubrutinib (an oral medicine) and CAR-T cell therapy can treat Richter syndrome, a type of lymphoma that develops in people with CLL/SLL. It may help shrink tumors and improve outcomes after the disease comes back or doesn’t respond to prior treatment.
This Phase 2 trial studies acalabrutinib, venetoclax, and durvalumab together for Richter transformation (a more aggressive lymphoma) that developed from CLL or SLL. The goal is to improve how well treatment works and how long people can respond.
This trial tests a new targeted therapy (pirtobrutinib) added to standard chemotherapy for a specific type of lymphoma. It aims to see if the combination improves outcomes for patients who have not been treated before.
Hear when a new Richter Syndrome trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.